Abstract
Expanding the range of biological drugs for the treatment of patients with severe asthma requires rationalizing a personalized approach to treatment to account for the potential risks of adverse events. Information on the development of drug-induced sarcoid-like syndrome during anti-IL-4, -13 therapy is limited to isolated publications and requires a detailed analysis of each specific clinical case. This is necessary to further develop a patient profile associated with higher risks of adverse events related to anti-IL-4, -13 therapy, as well as to develop a rational algorithm for dynamic laboratory and instrumental monitoring and to define its timing. The aim was to investigate the emergence of drug-induced sarcoid-like syndrome associated with anti-IL-4, -13 treatment in a patient with severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to evaluate the safety and efficacy profile of alternative biological therapies. Conclusion . The therapeutic potential of anti-IL-4, -13 therapy in patients with bronchial asthma and CRSwNP is undisputed. Given the risk of adverse events associated with biological therapy, strict frequent monitoring of laboratory and instrumental data is required. Further investigation of the efficacy and safety of biological therapy in asthma and CRSwNP will help determine the optimal timing of treatment response and monitoring intervals, identify possible predictors of adverse events, and develop personalized therapeutic approaches.